Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–23 of 23 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Daily Peritoneal Dialysis Clear all

Conditions: End Stage Renal Disease on Dialysis
Interventions: Empagliflozin 25 mg vs Placebo, Empagliflozin 10 MG; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: End Stage Renal Disease, Hypoalbuminemia, Malnutrition
Interventions: Protein Food Bar Intelligent Indulgence; Dietary Supplement
Lead sponsor: Satellite Healthcare; Other
Eligibility: 18 Years and older
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: Mountain View, California

Conditions: End Stage Kidney Disease, End Stage Renal Disease
Interventions: Assistance to perform Peritoneal Dialysis (PD) at home; Other
Lead sponsor: Satellite Healthcare; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 6
States / cities: Emeryville, California • Fremont, California • Milpitas, California + 3 more

Conditions: Renal Failure, Protein-Energy Malnutrition
Interventions: Whey protein supplement; Dietary Supplement
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 2
States / cities: Gainesville, Florida

Conditions: Chronic Kidney Disease
Interventions: Increasing Physical activity; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 6 Years to 20 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Peritoneal Dialysis Complication, Hyperphosphatemia, Hypoalbuminemia
Interventions: Sucroferric Oxyhydroxide Chewable Tablet; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 80 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Abscess, Wound Infection, Surgical Site Infection, Cellulitis
Interventions: Dalbavancin, Dalbavancin-matching Placebo; Drug
Lead sponsor: Durata Therapeutics Inc., an affiliate of Allergan plc; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 698 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 25
States / cities: Montgomery, Alabama • Anaheim, California • Long Beach, California + 18 more

Conditions: Peritoneal Dialysis, Hypertriglyceridemia
Interventions: Extraneal (7.5% icodextrin) Peritoneal Dialysis Solution; Drug
Lead sponsor: Vantive Health LLC; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 3
States / cities: Santa Clara, California • Michigan City, Indiana • Lincoln, Nebraska

Conditions: Anaemia
Interventions: GSK1278863; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Lakewood, Colorado • Minneapolis, Minnesota

Conditions: Kidney Failure, Chronic, Heart Failure
Interventions: Empagliflozin 25 mg thrice-weekly post-hemodialysis dosing, Empagliflozin 10 mg daily dosing; Drug
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Jackson, Mississippi

Conditions: Iron Deficiency Anemia
Interventions: Sodium Ferric Gluconate Complex, Oral Iron; Drug
Lead sponsor: Watson Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 19
States / cities: Birmingham, Alabama • Mesa, Arizona • Los Angeles, California + 16 more

Conditions: Kidney Failure
Interventions: Daily Peritoneal Dialysis, Days-off Peritoneal Dialysis; Procedure
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 10
States / cities: Torrance, California • Atlanta, Georgia • Evanston, Illinois + 6 more

Conditions: Anemia of End Stage Renal Disease
Interventions: MDGN201 TARGTEPO; Biological
Lead sponsor: Aevi Genomic Medicine, LLC, a Cerecor company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: End Stage Renal Disease, Gut Microbiome Dysbiosis
Interventions: P-inulin; Dietary Supplement
Lead sponsor: Ali Ramezani; Other
Eligibility: 21 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Washington D.C., District of Columbia

Conditions: Anaemia, Aspergillosis, Allergic Bronchopulmonary
Interventions: Daprodustat, rhEPO, Placebo, Iron therapy; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 2,964 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 126
States / cities: Huntsville, Alabama • Pine Bluff, Arkansas • Anaheim, California + 103 more

Conditions: Chronic Kidney Disease, Hyperparathyroidism, Secondary
Interventions: Cinacalcet hydrochloride, Standard of Care; Drug
Lead sponsor: Amgen; Industry
Eligibility: 28 Days to 2189 Days
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 17
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 14 more

Conditions: Dialysis, Anemia
Interventions: Roxadustat, Oral Iron, IV Iron; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: Northridge, California • Yuba City, California • Detroit, Michigan

Conditions: Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT)
Interventions: Paricalcitol; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 0 Years to 9 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 14
States / cities: Little Rock, Arkansas • Redwood City, California • Washington D.C., District of Columbia + 10 more

Conditions: Renal Failure
Interventions: elbasvir (50mg) / grazoprevir (100mg) (fixed dose combination); Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 40 Years to 70 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Gastroschisis
Interventions: SoC Staged Silo Closure, Peritoneal Dialysis Solution/Dextrose 1.5%; Procedure · Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 0 Hours to 12 Hours
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Chronic Kidney Disease, Hyperparathyroidism, Hyperparathyroidism, Secondary, Kidney Disease, Secondary Hyperparathyroidism
Interventions: cinacalcet capsule, placebo, Standard of Care; Drug
Lead sponsor: Amgen; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 18
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 14 more

Conditions: Peritoneal Dialysis Complication, Hypoalbuminemia, Malnutrition
Interventions: increased protein intake via natural foods, increase protein intake via protein supplements; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Riverside, California

Conditions: Hyperphosphatemia
Interventions: Niacinamide, Placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: St Louis, Missouri

Search by objective public record fields.

Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease

Impact of Providing High Protein Bar to Dialysis Patients With Low Serum Albumin

Assisted Peritoneal Dialysis: A Feasibility Study

Examining the Impact of High-protein Oral Supplement on Protein Status of Adults on Peritoneal Dialysis

Pedometers to Assess and Increase Physical Activity Among Children With Chronic Kidney Disease

Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients

Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Effect of Extraneal (Icodextrin)on Triglyceride Levels in PD Patients

Study to Assess the Pharmacokinetics of GSK1278863 in Subjects With End Stage Renal Disease Undergoing Peritoneal Dialysis

Empagliflozin in ESKD - A Feasibility Study

2 Doses of Ferrlecit Versus Oral Iron to Treat Iron-deficiency Anemia in Peritoneal Dialysis Patients.

Days-Off Versus Daily Initial Peritoneal Dialysis Prescription

TARGTEPO Treatment for Anemia in PD US Trial

Prebiotics in Peritoneal Dialysis

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)

Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism

Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment

A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)

Preemptive Treatment With Grazoprevir and Elbasvir for Donor HCV Positive to Recipient HCV Negative Kidney Transplant

Direct Peritoneal Resuscitation in Gastroschisis

Pediatric Chronic Kidney Disease Safety and Efficacy

The Effect of Natural Protein vs. Protein Supplements on Peritoneal Dialysis Patients

The Effect of Oral Niacinamide on Plasma Phosphorus Levels in Peritoneal Dialysis Patients